Synthetic Strategies toward SGLT2 Inhibitors
نویسندگان
چکیده
منابع مشابه
Mechanism of Action of Sglt2-inhibitors
T2DM individuals manifest a 2-3 times greater risk of CV events compared to non-diabetics, and CV mortality is responsible for ~70% of total mortality. In T2DM patients without MI, risk of CV death is similar to individuals without diabetes with prior MI.1 Although hyperglycemia is a strong risk factor for microvascular complications, it is a weak risk factor for CV disease (CVD), and intervent...
متن کاملSGLT2 Inhibitors and the Diabetic Kidney.
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotectio...
متن کاملSGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?
nents, can lead to de novo ESRD in subjects without identifiable ESRD risks. These data also increase the urgency to identify kidney toxic dietary components and if these components can promote ESRD even in subjects who have no identifiable risk factors. Diet remains a relatively underused component of the clinician’s armamentarium in the fight to prevent patients with CKD progressing to ESRD a...
متن کاملSGLT2 Inhibitors: A New Generation of Antidiabetic Drugs
The incidence of type 2 diabetes is markedly increasing worldwide. Despite a plethora of therapeutic options available for the treatment of type 2 diabetes, the ability to effectively normalize blood glucose levels and prevent long-term complications of diabetes remains elusive. There is intense search for new drugs for diabetes. One novel therapeutic class of antidiabetic drugs is sodium-gluco...
متن کاملPositioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recent addition to the therapeutic options available for the treatment of type 2 diabetes and became available after the introduction of incretin-based therapies, dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These agents have potential advantages with regard to their weight loss-promo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Organic Process Research & Development
سال: 2018
ISSN: 1083-6160,1520-586X
DOI: 10.1021/acs.oprd.8b00017